Time to Buy This Beaten-Down Biotech Stock?
Jun 26th 2012 6:28PM
Updated Jun 26th 2012 6:34PM
The following video is from today's MarketFoolery podcast, in which host Chris Hill, along with Charly Travers, Mike Olsen, and Joe Magyer, discuss the latest business news. After a federal court ruled in its favor, shares of Teva Pharmaceutical popped 6% on Monday while shares of Momenta Pharmaceuticals fell 20%. In this segment, Charly analyzes the competitive landscape in the biotech industry and shares why he believes Momenta is a company in great shape, despite having a bad day.
With shares up this week, dividend payer Teva Pharmaceutical isn't exactly trading at a bargain-basement price. To find stocks that are, check out The Motley Fool's free report "2 Dirt Cheap Stocks With HUGE Dividends." You can get analysis of a market leader in payment systems and a high-yielding energy company by accessing this report. It won't be available forever, so click here -- it's free.
The article Time to Buy This Beaten-Down Biotech Stock? originally appeared on Fool.com.Chris Hill owns no shares of any of the companies mentioned. The Motley Fool owns shares of Momenta Pharmaceuticals. Motley Fool newsletter services have recommended buying shares of Momenta Pharmaceuticals. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.